
    
      This is a multi-center study that will enroll approximately 36 subjects. The study consists
      of three periods of two days of dosing each. The study will evaluate 5 potential dose
      regimens. Each subject will receive a randomized sequence of treatments over three periods,
      with placebo treatment in one period and two different active dose regimens in the other two
      periods. There will be 5 to 12 days of outpatient washout between treatment periods. Subjects
      will continue their current treatment on metformin throughout the study. Subjects will
      monitor blood glucose levels daily via glucometer during oupatient washout periods. A
      follow-up visit will occur between 5 and 10 days after the last period of the study.
    
  